Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Annual Review of Cancer Biology is a pivotal journal published by Annual Reviews, specializing in the rapidly evolving field of cancer research. With an impact factor positioned in the distinguished Q1 quartile of Cancer Research, Cell Biology, and Oncology categories, this journal ensures that it showcases the highest quality of scholarly contributions. Indexed in Scopus, it ranks among the top in its fields, reflecting its strong influence and relevance, with remarkable percentiles indicating its esteemed position within the research community. Although not an open-access journal, it provides a comprehensive platform for advancing the frontiers of cancer biology through rigorously curated reviews, highlighting key developments, breakthroughs, and future directions that inform both academia and clinical applications. As a valuable resource for researchers, professionals, and students, the Annual Review of Cancer Biology serves as an essential guide for understanding and addressing the complexities of cancer biology today.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

BREAST CANCER RESEARCH, published by BMC, is a prestigious open-access journal dedicated to advancing the field of oncology with a specific focus on breast cancer. Since its inception in 1999, the journal has established itself as a leading platform for disseminating high-quality research, with an impressive impact factor and recognition in the Q1 category for both Cancer Research and Oncology as of 2023. The journal is ranked 45th out of 404 in the field of Medicine _ Oncology and 37th out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, placing it in the top echelons of research quality and relevance at 88th and 84th percentiles, respectively. BREAST CANCER RESEARCH is committed to facilitating rapid and open access to groundbreaking findings, making it an invaluable resource for researchers, healthcare professionals, and students striving to enhance their understanding of breast cancer mechanisms, treatments, and prevention strategies. With its base in the United Kingdom, the journal continues to foster international collaborations and discussions aimed at improving patient outcomes and enriching cancer research worldwide.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

Cellular and Molecular Biology is a prominent academic journal published by C M B ASSOC, specializing in the dynamic fields of cellular and molecular biology. Established in 1977, this journal has consistently aimed to disseminate groundbreaking research that contributes to our understanding of biochemical processes, cell dynamics, and molecular mechanisms governing life. With its ISSN 0145-5680 and E-ISSN 1165-158X, the journal plays a vital role in the exchange of innovative ideas, evidenced by its coverage of research from 1977 to 2024. Although currently categorized in the Q4 quartile for major disciplines such as Biochemistry and Cell Biology, it is dedicated to fostering the development of the field by welcoming submissions that challenge the conventional understanding and lead to novel insights. Researchers and academics looking to contribute to or stay updated in the rapidly evolving landscape of molecular biology will find this journal a valuable resource for connecting with a global community of scientists.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.